340
Participants
Start Date
October 31, 2010
Primary Completion Date
January 31, 2015
Study Completion Date
January 31, 2015
ONO-4641
Subjects will be administered with ONO-4641 at a dose of 0.15 milligram (mg) in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
ONO-4641
Subjects will be administered with ONO-4641 at a dose of 0.10 mg in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
ONO-4641
Subjects will be administered with ONO-4641 at a dose of 0.05 mg in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
ONO-4641
Subjects will receive placebo in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
ONO-4641
Subjects will receive placebo in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
ONO-4641
Subjects will receive placebo in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
Brugge Clinical Site 203, Bruges
La Louviere Clinical Site 201, La Louvière
Rochester Clinical Site 108, Rochester
Praha 5 Clinical Site 213, Prague
Girona Clinical Site 254, Girona
Philadelphia Clinical Site 120, Philadelphia
Vinnytsya Clinical Site 342, Vinnytsia
Raleigh Clinical Site 103, Raleigh
Charlotte Clinical Site 125, Charlotte
Ormond Beach Clinical Site 129, Ormond Beach
Sarasota Clinical Site 116, Sarasota
Marburg Clinical Site 228, Marburg
Glessen Clinical Site 221, Glessen
Knoxville Clinical Site 134, Knoxville
Sevilla Clinical Site 256, Seville
Akron Clinical Site 112, Akron
Indianapolis Clinical Site 121, Indianapolis
Fort Wayne Clinical Site 111, Fort Wayne
Bilbao Clinical Site 255, Bilbao
Detroit Clinical Site 104, Detroit
Farmington Hills Clinical Site 126, Farmington Hills
Dnipropetrovsk Clinical Site 341, Dnipropetrovsk
Pardubice Clinical Site 211, Pardubice
Northbrook Clinical Site 135, Northbrook
Tubingen Clinical Site 226, Tübingen
Round Rock Clinical Site 107, Round Rock
Aurora Clinical Site 132, Aurora
Fort Collins Clinical Site 123, Fort Collins
Tucson Clinical Site 133, Tucson
Albuquerque Clinical Site 106, Albuquerque
Moscow Clinical Site 332, Moscow
Nizhniy Novgorod Clinical Site 321, Nizhny Novgorod
Moscow Clinical Site 330, Moscow
St. Petersburg Clinical Site 325, Saint Petersburg
Kazan Clinical Site 333, Kazan'
Samara Clinical Site 329, Samara
Ufa Clinical Site 326, Ufa
Novosibirsk Clinical Site 324, Novosibirsk
Fairfield Clinical Site 110, Fairfield
Lebanon Clinical Site 115, Lebanon
Vancouver Clinical Site 131, Vancouver
Gatineau Clinical Site 114, Gatineau
Kanto Region Clinical Site 404, Kanto
Kanto Region Clinical Site 405, Kanto
Kanto Region Clinical Site 406, Kanto
Kanto Region Clinical Site 409, Kanto
Kinki Region Clinical Site 401, Kinki
Kinki Region Clinical Site 407, Kinki
Kinki Region Clinical Site 408, Kinki
Tohoku Region Clinical Site 403, Tōhoku
Tohoku Region Clinical Site 410, Tōhoku
Greenfield park Clinical Site 109, Greenfield Park
Montreal Clinical Site 101, Montreal
Montreal Clinical Site 102, Montreal
Olomouc Clinical Site 212, Olomouc
Leipzig Clinical Site 229, Leipzig
Athens Clinical Site 243, Athens
Bialystok Clinical Site 305, Bialystok
Czeladz Clinical Site 303, Czeladź
Gdansk Clinical Site 302, Gdansk
Katowice Clinical Site 309, Katowice
Krakow Clinical Site 307, Krakow
Lodz Clinical Site 306, Lodz
Plewiska Clinical Site 304, Plewiska
Warszawa Clinical Site 308, Warsaw
Barcelona Clinical Site 252, Barcelona
Barcelona Clinical Site 253, Barcelona
Hospitalet de Llobregat Clinical Site 251, L'Hospitalet de Llobregat
Kyiv Clinical Site 344, Kyiv
Lviv Clinical Site 343, Lviv
Lead Sponsor
Collaborators (1)
Merck KGaA, Darmstadt, Germany
INDUSTRY
Ono Pharmaceutical Co. Ltd
INDUSTRY
EMD Serono
INDUSTRY